Fig. 4.

Docetaxel and NHS-IL-12 combination therapy exert significant antitumor activity in the MC38 and EMT6 tumor models. (A) Graphical representation of experimental design in the MC38 tumor model. (B) Tumor volumes of MC38 tumor-bearing mice in the untreated, docetaxel, NHS-IL-12, and docetaxel + NHS-IL-12 treated cohorts. Numbers at the bottom right of graphs indicate animals that were tumor-free at end of study. (C) Average tumor growth curves of MC38 tumor-bearing mice receiving no treatment (black line; n = 5), docetaxel (red line; n = 5), NHS-IL-12 (blue line; n = 5) or docetaxel and NHS-IL-12 combination therapy (purple line; n = 6). (D) Survival proportions of MC38 tumor-bearing mice receiving no treatment (black line; n = 5), docetaxel (red line; n = 5), NHS-IL-12 (blue line; n = 5) or docetaxel and NHS-IL-12 combination therapy (purple line; n = 6) with median survival and p value relative to untreated control mice indicated in parentheses. (E) Graphical representation of experimental design using the EMT6 tumor model. (F) Tumor volumes of EMT6 tumor-bearing mice in the untreated, docetaxel, NHS-IL-12 and docetaxel + NHS-IL-12 treated cohorts. (G) Average tumor volumes of EMT6 tumor-bearing mice receiving no treatment (black line; n = 9), docetaxel (red line; n = 10), NHS-IL-12 (blue line; n = 10) or docetaxel + NHS-IL-12 combination therapy (purple line; n = 9). (H) Survival proportions of EMT6 tumor-bearing mice with median survival and p value relative to untreated control mice indicated in parentheses. Undef. = undefined. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001